Medexus Pharmaceuticals (MDP) Q1 2025 earnings summary

Executive summary

• Fiscal Q1 2025 delivered net income of $2 million, up $1.3 million year-over-year, and adjusted EBITDA of $6.1 million, down from $6.6 million last year, with revenue at $27.3 million, a 13.6% decrease mainly due to lower Rasuvo and IXINITY sales, partially offset by Rupall growth.

• Cost reduction initiatives implemented in January 2024 led to lower operating expenses and improved cost structure, aiding net income growth.

• Operating income was $4.0 million, down 16.7% year-over-year.

• Available liquidity increased to $8.5 million as of June 30, 2024, up from $5.3 million at March 31, 2024.

Financial highlights

• Gross profit was $14.8 million, down from $17.2 million year-over-year, with gross margin steady at 54.4% versus 54.6% last year.

• Operating cash flow reached a record $8.2 million, with cash on hand rising to $8.5 million as of June 30, 2024.

• Selling and administrative expenses dropped to $10.3 million from $11.9 million year-over-year.

• Outstanding debt under BMO credit facilities totaled $48.3 million, with both facilities maturing in March 2026.

Outlook and guidance

• Gross and EBITDA margins are expected to remain stable for the near term.

• FDA review of treosulfan NDA is expected to conclude by October 30, 2024, with a commercial launch targeted for H1 2025 if approved.

• No significant Treosulfan revenue expected until early fiscal 2026 (Q2 2025 at the earliest).

• Rupall faces generic competition in Canada after January 2025, likely resulting in price reductions, but not a sharp drop.

• IXINITY and Rasuvo expected to face continued revenue pressure from competition and statutory discounts.